Association analysis between incidence of adverse events and time-concentration profiles of trace metals during platinum-based cancer chemotherapy
| Project/Area Number |
17K08474
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Osaka University of Pharmaceutical Sciences |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
細畑 圭子 大阪薬科大学, 薬学部, 准教授 (10547962)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | プラチナ / 癌化学療法 / バイオメタル / デキサメタゾン / 抗癌剤 / 薬学 |
|---|
| Outline of Final Research Achievements |
The administration of platinum-containing drugs can alter the concentration of trace metals including iron in the body fluids, which might associate various physiological reactions. Systemic iron (Fe) homeostasis is controlled by hepcidin, that acts as a negative regulator of Fe release. The serum concentration of hepcidin was elevated in the patients following the commencement of CDDP-based chemotherapy, although hepcidin might be released into the bloodstream as a secondary reaction to excessive systemic Fe. Meanwhile, dexamethasone, which is generally used as a prophylactic antiemetic therapy, can partly contribute to the changes in the serum concentrations of trace metals during anticancer chemotherapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、プラチナ系抗癌剤によって引き起こされる骨髄抑制や神経障害などの用量制限毒性のメカニズム解明に向け、生体内に存在する必須微量金属元素（バイオメタル）の活用の可能性を探った。プラチナ系抗癌剤を用いた化学療法施行時に変動するバイオメタルは、支持療法で使用される薬剤によっても影響されることが明らかとなり、治療プロトコールに応じた副作用予防法を確立する上で有益な知見と考えられる。副作用の予防や軽減はQOLを著しく向上させ、従来中断を余儀なくされていた化学療法を持続的に実施できるようになり、最終的には癌治癒率の向上や延命率の向上によって社会に対して貢献できるものと期待される。
|
Report
(4 results)
Research Products
(38 results)
-
[Journal Article] Association between dexamethasone treatment and alterations in serum concentrations of trace metals.2020
Author(s)
Kazuhiko Yamashita, Takashi Ogihara, Maho Hayashi, Takayuki Nakagawa, Yuma Ishizaki, Manabu Kume, Ikuko Yano, Riho Niigata, Jun Hiraoka, Hiroyuki Yasui, Tsutomu Nakamura.
-
Journal Title
Related Report
Peer Reviewed
-
-
-
[Journal Article] Pharmacokinetics of oxaliplatin in a hemodialysis patient with metastatic colon cancer.2019
Author(s)
Yoshiaki Nagatani, Yoshinori Imamura, Tsutomu Nakamura, Kazuhiko Yamashita, Mamoru Okuno, Hiroyuki Yasui, Jun Hiraoka, Riho Niigata, Keiji Kono, Yasuko Hyogo, Hirotaka Suto, Kei Takenaka, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hironobu Minami.
-
Journal Title
Int J Oncol Res.
Volume: 2
Pages: 017-017
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.2018
Author(s)
Mayako Uchida, Tsutomu Nakamura, Yoko Makihara, Kimitaka Suetsugu , Hiroaki Ikesue, Yasuo Mori, Koji Kato, Motoaki Shiratsuchi, Keiko Hosohata, Toshihiro Miyamoto, Koichi Akashi.
-
Journal Title
Pharmazie.
Volume: 73
Pages: 304-308
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
